Analysis of the clinical trial results of the flavonoid effects on some cellular immunity indicators in children and adults

In the scope of this paper, an analysis of the clinical trial results assessing the clinical and immunological efficacy of the effects of flavonoids on some indicators of immunity in children and adults is given.

AIM

The aim of the study was to evaluate the effects of flavonoids on the cellular component of the immune system in children and adults with viral and viral-bacterial diseases by using meta-analysis and statistical analysis of the clinical findings.

MATERIALS AND METHODS

The analysis comprises 5 scientific sources with the results of controlled clinical trials involving 412 children and 15 sources involving 1493 adult patients during the period from 2003 to 2017. In analysis Student's t-test was applied.

RESULTS

The data obtained indicate the efficacy of flavonoids in the treatment of viral and viral-bacterial diseases in children and adults. The administration of flavonoids (Proteflazid®, Immunoflazid®, Flavozid®) in the treatment of children with acute respiratory diseases and adults with HHV infection contributes to the normalization of cellular immunity indicators, the HHV infections symptom resolution, and the relapse rate reduction of genital herpes caused by HHV infection.

CONCLUSIONS

Therapy with such medical products as Proteflazid®, Immunoflazid®, Flavozid® helps to improve the clinical status and normalize the cellular immunity indicators in patients who were administered a treatment course.

Proteflazid®: outcome analysis of clinical trials studying the impact of human herpesvirus infection on some cellular immunity indicators and gestation course in women

An outcome analysis of the clinical trials evaluating the clinical and immunological efficacy of the drug Proteflazid® in the treatment of diseases associated with herpesvirus infection in pregnant women is presented.

AIM

Objective of the study was to evaluate the effects of Proteflazid® on the cellular component of the immune system and gestation course in women with HHV infection by using meta-analysis and statistical analysis (based on Student's t-test) of the clinical findings.

MATERIALS AND METHODS

The analysis comprises 5 scientific sources with the results of controlled clinical trials involving 234 pregnant women during the period from 2003 to 2012.

RESULTS

The obtained data prove the efficacy of the preparation Proteflazid ® in treating pregnant women with HHV infection. Administration of the drug Proteflazid® in the treatment of herpesvirus infection in pregnant women contributes to the cellular immunity normalization, which in turn has a positive effect on the course and outcome of pregnancy.

CONCLUSIONS

Therapy with the drug Proteflazid® is etiologically and pathogenetically substantiated, contributes to the normalization of cellular immunity parameters, which, in turn, has a positive effect on the course and outcome of pregnancy.

PROTEFLAZID®: clinical studies as evidence base of its antiviral activity

The article contains the results of many years of clinical studies of efficiency and safety of the preparation Proteflazid®, obtained from the wild cereals Deschampsia caespitosa L. and Calamagrotis epigeios L. Proteflazid® has direct antiviral and anti-relapsing effects in various disease of viral etiology, registered in more than 230 clinical studies.

Proteflazid®: treatment of herpesvirus and mixed infections. Meta-analysis of clinical trials results

There is a meta-analysis of clinical trials results concerning the evaluation of efficiency of the drug Proteflazid® (drops) in the treatment of adult patients with herpesvirus and mixed infections.

AIM

Objective of the study: to evaluate the clinical efficacy of the drug Proteflazid® in a treatment of herpesvirus (HSV-1, HSV-2) and mixed infections in adults by meta-analysis of clinical trials.

MATERIALS AND METHODS

In meta-analysis, 16 scientific sources with results of controlled studies with participation of 1336 patients over 18 y.o. during 2003-2015 are included.

RESULTS

Obtained data are indicative of efficiency of the drug Proteflazid® in the treatment of patients with herpesvirus and mixed infections. Proteflazid® induces improvement in the main clinical signs of diseases, promotes elimination of herpesviruses from organism and prevention of relapses.

CONCLUSIONS

Proteflazid® in the therapy of various clinical forms of HHVs infection promotes the improvement in the main clinical signs of diseases, elimination of HSV-1 and HSV-2; prevention of relapses of diseases (ophthalmoherpes, genital herpes) after completion of the treatment. Therapy of mixed infections (HSV, bacteria, protozoa, fungi) using the drug Proteflazid® promotes improvement in the main clinical signs of diseases, improvement in vaginal mircoflora condition and improvement in local changes in the cervix in women with inflammatory diseases of genital organs as well as in prevention of relapses of genital inflammatory diseases and chronic pyelonephritis.